iScience (Jun 2024)

Human gut Actinobacteria boost drug absorption by secreting P-glycoprotein ATPase inhibitors

  • Than S. Kyaw,
  • Chen Zhang,
  • Moriah Sandy,
  • Kai Trepka,
  • Shenwei Zhang,
  • Luis A. Ramirez Hernandez,
  • Lorenzo Ramirez,
  • Janice J.N. Goh,
  • Kristie Yu,
  • Vincent Dimassa,
  • Elizabeth N. Bess,
  • Jacob G. Brockert,
  • Darren S. Dumlao,
  • Jordan E. Bisanz,
  • Peter J. Turnbaugh

Journal volume & issue
Vol. 27, no. 6
p. 110122

Abstract

Read online

Summary: Drug efflux transporters are a major determinant of drug efficacy and toxicity. A canonical example is P-glycoprotein (P-gp), an efflux transporter that controls the intestinal absorption of diverse compounds. Despite a rich literature on the dietary and pharmaceutical compounds that impact P-gp activity, its sensitivity to gut microbial metabolites remains an open question. Surprisingly, we found that the cardiac drug-metabolizing gut Actinobacterium Eggerthella lenta increases drug absorption in mice. Experiments in cell culture revealed that E. lenta produces a soluble factor that post-translationally inhibits P-gp ATPase efflux activity. P-gp inhibition is conserved in the Eggerthellaceae family but absent in other Actinobacteria. Comparative genomics identified genes associated with P-gp inhibition. Finally, activity-guided biochemical fractionation coupled to metabolomics implicated a group of small polar metabolites with P-gp inhibitory activity. These results highlight the importance of considering the broader relevance of the gut microbiome for drug disposition beyond first-pass metabolism.

Keywords